Answers are grounded in this paper and cite their sources.
We read with great interest the study by Ho et al. which demonstrated that hepatocellular carcinoma (HCC) patients with simple steatosis [metabolic dysfunction-associated steatotic liver disease (MASLD) without metabolic dysfunction-associated steatohepatitis (MASH)] had a significant survival advantage after hepatectomy, whereas progression to MASH negated this benefit[1]. Notably, in the subgroup of HBsAg-positive patients, the presence of MASLD or MASH did not significantly affect overall survival (OS) or recurrence-free survival (RFS).
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: